Mahmoud Al-Khrasani
Overview
Explore the profile of Mahmoud Al-Khrasani including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
65
Citations
490
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Papp Z, Ribiczey P, Kato E, Toth Z, Varga Z, Giricz Z, et al.
Biomedicines
. 2025 Jan;
13(1).
PMID: 39857655
Background: N-methyl-D-aspartate type glutamate receptors (NMDARs) are fundamental to neuronal physiology and pathophysiology. The prefrontal cortex (PFC), a key region for cognitive function, is heavily implicated in neuropsychiatric disorders, positioning...
2.
Costanzo G, Cosentino G, Grasso M, Patamia V, Zuccala S, Coco A, et al.
RSC Med Chem
. 2025 Jan;
PMID: 39777289
Inflammatory pain represents one of the unmet clinical needs for patients, as conventional therapies cause several side effects. Recently, new targets involved in inflammatory pain modulation have been identified, including...
3.
Galambos A, Essmat N, Lakatos P, Szucs E, Boldizsar Jr I, Abbood S, et al.
Int J Mol Sci
. 2024 Oct;
25(20).
PMID: 39456918
Opioid analgesic tolerance (OAT), among other central side effects, limits opioids' indispensable clinical use for managing chronic pain. Therefore, there is an existing unmet medical need to prevent OAT. Extrasynaptic...
4.
Denaro S, DAprile S, Torrisi F, Zappala A, Marrazzo A, Al-Khrasani M, et al.
Inflamm Res
. 2024 Aug;
73(10):1711-1726.
PMID: 39095656
Background And Objective: Neuropathic pain is a chronic condition characterized by aberrant signaling within the somatosensory system, affecting millions of people worldwide with limited treatment options. Herein, we aim at...
5.
Hosztafi S, Galambos A, Koteles I, Karadi D, Furst S, Al-Khrasani M
Int J Mol Sci
. 2024 Jul;
25(14).
PMID: 39063024
Over the past decades, extensive preclinical research has been conducted to develop vaccinations to protect against substance use disorder caused by opioids, nicotine, cocaine, and designer drugs. Morphine or fentanyl...
6.
Galambos A, Papp Z, Boldizsar I, Zador F, Koles L, Harsing Jr L, et al.
Biomedicines
. 2024 Feb;
12(2).
PMID: 38398023
The development of opioid tolerance in patients on long-term opioid analgesic treatment is an unsolved matter in clinical practice thus far. Dose escalation is required to restore analgesic efficacy, but...
7.
Essmat N, Karadi D, Zador F, Kiraly K, Furst S, Al-Khrasani M
Molecules
. 2023 Dec;
28(23).
PMID: 38067494
Opioid receptor agonists, particularly those that activate µ-opioid receptors (MORs), are essential analgesic agents for acute or chronic mild to severe pain treatment. However, their use has raised concerns including,...
8.
Essmat N, Galambos A, Lakatos P, Karadi D, Mohammadzadeh A, Abbood S, et al.
Pharmaceuticals (Basel)
. 2023 Aug;
16(8).
PMID: 37631030
The current treatment of neuropathic pain (NP) is unsatisfactory; therefore, effective novel agents or combination-based analgesic therapies are needed. Herein, oral tolperisone, pregabalin, and duloxetine were tested for their antinociceptive...
9.
Costanzo G, Turnaturi R, Parenti C, Spoto S, Piana S, Dichiara M, et al.
Molecules
. 2023 Jun;
28(12).
PMID: 37375382
In this work, we report on the in vitro and in vivo pharmacological properties of LP1 analogs to complete the series of structural modifications aimed to generate compounds with improved...
10.
Schmidhammer H, Al-Khrasani M, Furst S, Spetea M
Molecules
. 2023 Jun;
28(12).
PMID: 37375318
Opioids are considered the most effective analgesics for the treatment of moderate to severe acute and chronic pain. However, the inadequate benefit/risk ratio of currently available opioids, together with the...